We provide the latest news
from the world of economics and financeBRIDGEBIO PHARMA ($BBIO) posted quarterly earnings results on Tuesday, April 29th. The company reported earnings of -$0.88 per share, beating estimates of -$0.94 by $0.06. The company also reported revenue of $116,630,000, beating estimates of $62,676,409 by $53,953,591.
You can see Quiver Quantitative's $BBIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BRIDGEBIO PHARMA insiders have traded $BBIO stock on the open market 21 times in the past 6 months. Of those trades, 0 have been purchases and 21 have been sales.
Here’s a breakdown of recent trading of $BBIO stock by insiders over the last 6 months:
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
We have seen 151 institutional investors add shares of BRIDGEBIO PHARMA stock to their portfolio, and 109 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.